Medication adherence: A call for action - 31/08/11
, Bradi B. Granger, RN, PhD d, Phil Mendys, Pharm D e, Ralph Brindis, MD f, Rebecca Burkholder, JD g, Susan M. Czajkowski, PhD h, Jodi G. Daniel, JD, MPH i, Inger Ekman, PhD j, Michael Ho, MD k, Mimi Johnson, MPhil g, Stephen E. Kimmel, MD, MSCE l, Larry Z. Liu, MD, PhD m, John Musaus n, William H. Shrank, MD, MSHS o, Elizabeth Whalley Buono, RN, JD n, Karen Weiss p, Christopher B. Granger, MD qRiassunto |
Poor adherence to efficacious cardiovascular-related medications has led to considerable morbidity, mortality, and avoidable health care costs. This article provides results of a recent think-tank meeting in which various stakeholder groups representing key experts from consumers, community health providers, the academic community, decision-making government officials (Food and Drug Administration, National Institutes of Health, etc), and industry scientists met to evaluate the current status of medication adherence and provide recommendations for improving outcomes. Below, we review the magnitude of the problem of medication adherence, prevalence, impact, and cost. We then summarize proven effective approaches and conclude with a discussion of recommendations to address this growing and significant public health issue of medication nonadherence.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 162 - N° 3
P. 412-424 - settembre 2011 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
